Research Papers: Immunology:
Andrographolide ameliorates OVAinduced lung injury in mice by suppressing ROSmediated NFκB signaling and NLRP3 inflammasome activation
PDF | Full Text | How to cite
Metrics: PDF 4038 views | Full Text 5920 views
Shuang Peng1,*, Jian Gao1,*, Wen Liu1, Chunhong Jiang2, Xiaoling Yang2, Yang Sun1, Wenjie Guo1 and Qiang Xu1
1 State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China
2 State Key Laboratory of Innovative Nature Medicine and TCM Injections, Jiangxi Qingfeng Pharmaceutical Co., Ltd., Ganzhou, China
* These authors have contributed equally to this work
Correspondence to:
Qiang Xu, email:
Wenjie Guo, email:
Yang Sun, email:
Keywords: andrographolide; asthma; NF-κB; NLRP3; ROS; Immunology and Microbiology Section; Immune response; Immunity
Received: August 15, 2016 Accepted: October 14, 2016 Published: October 26, 2016
Abstract
In this study, we attempted to explore the effect and possible mechanism of Andrographolide on OVA-induced asthma. OVA challenge induced significant airway inflammatory cell recruitment and lung histological alterations, which were ameliorated by Andrographolide. The protein levels of cytokines in bron-choalveolar fluid (BALF) and serum were reduced by Andrographolide administration as well as the mRNA levels in lung tissue. Mechanically, Andrographolide markedly hampered the activation of nuclear factor-κB (NF-κB) and NLRP3 inflammasome both in vivo and vitro thus decreased levels of TNF-α and IL-1β. Finally, we confirmed that ROS scavenging was responsible for Andrographolide’s inactivation of NF-κB and NLRP3 inflammasome signaling. Our study here revealed the effect and possible mechanism of Andrographolide on asthma, which may represent a new therapeutic approach for treating this disease.